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Abstract
Background: An estimated 10% of tuberculosis (TB) deaths are attributable to problematic alcohol use globally,
however the causal pathways through which problem alcohol use has an impact on TB treatment outcome is not
clear. This study aims to improve understanding of these mechanisms. Specifically, we aim to 1) assess whether
poor TB treatment outcomes, measured as delayed time-to-culture conversion, are associated with problem alcohol
use after controlling for non-adherence to TB pharmacotherapy; and 2) to determine whether pharmacokinetic (PK)
changes in those with problem alcohol use are associated with delayed culture conversion, higher treatment
failure/relapse rates or with increased toxicity.
Methods: Our longitudinal, repeated measures, prospective cohort study aims to examine the associations
between problem alcohol use and TB treatment outcomes and to evaluate the effect of alcohol on the PK and
pharmacodynamics (PD) of TB drugs. We will recruit 438 microbiologically confirmed, pulmonary TB patients with
evidence of rifampicin susceptibility in Worcester, South Africa with 200 HIV uninfected patients co-enrolled in the
PK aim. Participants are followed for the six months of TB treatment and an additional 12 months thereafter, with
sputum collected weekly for the first 12 weeks of treatment, alcohol consumption measures repeated monthly in
concert with an alcohol biomarker (phosphatidylethanol) measurement at baseline, and in person directly observed
therapy (DOT) using real-time mobile phone-based adherence monitoring. The primary outcome is based on time
to culture conversion with the second objective to compare PK of first line TB therapy in those with and without
problem alcohol use.
Discussion: Globally, an urgent need exists to identify modifiable drivers of poor TB treatment outcomes. There is a
critical need for more effective TB treatment strategies for patients with a history of problem alcohol use. However, it is
not known whether poor treatment outcomes in alcohol using patients are solely attributable to noncompliance. This
study will attempt to answer this question and provide guidance for future TB intervention trials.
Trial registration: Clinicaltrials.gov Registration Number: NCT02840877. Registered on 19 July 2016.
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Background
Tuberculosis (TB) is the leading cause of death due to an
infectious disease globally. In 2016 there were an esti-
mated 10.4 million new TB cases, of which 4.7% were at-
tributable to harmful use of alcohol [1]. Problem alcohol
use, a volume or pattern of alcohol use resulting in ad-
verse health outcomes, is a key driver of poor TB treat-
ment response [2]. In comparison to patients who do not
consume alcohol, those who do consume alcohol, and es-
pecially those who engage in heavy episodic drinking, have
been shown to have delayed culture conversion and higher
rates of treatment failure, relapse and death [3].
The causal pathways by which problem alcohol use
affect TB treatment response, however, are poorly under-
stood. This is due largely to difficulties in studying pa-
tients with alcohol-related problems and a lack of detailed
data on their TB medication adherence. Heavy alcohol use
impacts retention in care and is associated with missed
DOT visits [4], with one study showing that MDR TB pa-
tients who consumed alcohol during treatment on average
missed 18 more intensive phase doses [5]. In order to
improve individual TB treatment outcomes, decrease
transmission, and guide future treatment intervention
strategies, we urgently need an improved understanding
of the relationship between alcohol and TB. One potential
mechanism for worse TB outcomes is poor treatment
adherence and loss to follow up [2], yet observational and
animal studies suggest biological mechanisms are also
contributing to the association between alcohol use and
poor TB clinical outcomes.
Mouse models have shown that compared to controls,
ethanol-consuming mice have significantly higher myco-
bacterial burden and impaired granuloma formation [6],
as well as impaired response to BCG vaccination [7]. Add-
itionally, alcohol has been shown to inhibit phagocytic
and bactericidal activity of macrophages [8], decrease the
number and function of dendritic cells [9] and neutrophils
[10], and modulate T cell function [9], B cells, cytokine
production and the interferon gamma pathway [6]. In
vitro and in vivo data support the impact of alcohol on
the immune system as a biological mechanism for poor
TB clinical outcomes in those who drink alcohol. Further-
more, chronic heavy drinking is associated with inhibition
of phagocytosis and decreased production of growth fac-
tors amongst innate immune cells in a dose and time
dependent manner [11], suggesting that chronic alcohol
use has a greater detrimental effect on the immune re-
sponse to TB. While these models support the concept
that problem alcohol users who consistently take their
medications will have worse treatment outcomes than
those without problem alcohol use, this hypothesis must
still be confirmed in human studies.
Another hypothesized biological mechanism to explain
the harmful impact of problem alcohol use on TB
clinical outcomes is alcohol’s influence on the pharma-
cokinetics (PK) and pharmacodynamics (PD) of TB
drugs. A recent meta-analysis concluded that studies
with lower default rates did not differ significantly in mi-
crobiologic failure, acquired drug resistance, or relapse
compared to studies with higher default rates, suggesting
that rather than adherence, the bioavailability of antitu-
berculosis medications plays an important role in TB
outcomes [12]. Furthermore, using the TB hollow-fiber
system model in concert with Monte Carlo simulations
modelling of degrees of noncompliance, a recent study
showed poor adherence was associated with microbio-
logic failure only when nonadherence exceeded 60%,
similarly supporting PK variability as the explanation for
acquired drug resistance [13]. While still theoretical for
comorbid problem alcohol use, studies of patients with
TB and HIV have shown that decreased antitubercular
drug absorption [14] and altered PK leads to TB drug re-
sistance [15].
Alcohol has been shown to alter the intestinal absorp-
tion of second-line antituberculosis medications [16, 17];
however, the pathway to bioavailability is further compli-
cated by protein binding and first pass metabolism
which may also prove to be affected by alcohol use.
Studies on the impact of alcohol on the bioavailability of
isoniazid have been contradictory [18–20], while a study
of patients with slow clinical response to treatment, fail-
ure or early relapse found that alcohol use was associ-
ated with higher rifampin serum concentrations [21]. A
detailed analysis of the PK and PD of all four TB drugs
in patients with problem alcohol use will allow for an
improved understanding of which TB drugs are most
impacted, leading to optimized dosing and treatment
duration or possible substitutions for individual drugs
that are consistently performing poorly in this popula-
tion at high risk for resistance and treatment failure. The
goal of this study is therefore to clarify the causal mech-
anisms underlying the deleterious effects of problem al-
cohol use on TB treatment response.
Primary objectives
The Tuberculosis Treatment and Alcohol Use Study
(TRUST) has two specific aims. The first is to assess
whether poor TB treatment outcomes, measured as de-
layed time-to-culture conversion, are associated with
problem alcohol use after controlling for non-adherence.
We hypothesize that poor TB treatment outcomes are
associated with problem alcohol use and that end organ
damage due to chronic alcohol use, rather than effects
of acute ingestion, will be the strongest predictor of poor
treatment outcomes after controlling for adherence.
The second aim is to compare the PK of anti-tuberculous
medications in those with and without problem alcohol
use, and to determine whether these PK changes are
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associated with delayed culture conversion, higher treat-
ment failure/relapse rates, or with increased toxicity. We
hypothesize that persons with problem alcohol use will
have altered peak drug concentration (Cmax) and area
under the curve (AUC) due to alcohol’s effects on drug
absorption and metabolism and that these PK changes will
be associated with poor clinical outcomes and increased
toxicity.
Methods
TRUST is a prospective, longitudinal, repeated-measures
study which plans to recruit 438 culture-positive,
pulmonary TB participants in Worcester, South Africa
and follow them over an 18-month period (6-month
treatment period, 12 months post-treatment; Fig. 1).
Study site selection
This study is recruiting participants receiving treatment
for TB from the Worcester Community Day Centre, a
clinic in Worcester which is the main town of the
Breede Valley municipality in the Western Cape Prov-
ince of South Africa. In this province, TB is the leading
cause of natural death [22] and, in South Africa in
general, the TB epidemic is intertwined with problem al-
cohol use. Between 2000 and 2014, alcohol-attributable
TB incidence increased by more than 100%, a greater in-
crease than any other country studied and more than
five times higher than the global average [23]. In the
semirural farming community of Worcester, problem al-
cohol use is common [24]. A recent study reported an
incidence of 16–19% in females and 33–56% in males in
this area [25]. The legacy of the “dop” system, whereby
farm workers were paid in part with wine, has led to a
pattern of heavy, episodic drinking in this farming com-
munity [26]. The high prevalence of alcohol problems
and TB makes this health district a uniquely appropriate
setting to study how alcohol use impacts TB outcomes.
Participant eligibility criteria
Individuals initiating treatment for smear, Xpert or cul-
ture positive drug susceptible pulmonary TB, who are
willing to participate and provide written informed
consent, are at least 15 years old and expected to remain
in the local area for the next 2 years are eligible to
participate in this study. Participants will be excluded
from this study if they have rifampin resistance, epilepsy,
Fig. 1 TRUST study schedule for participant follow up
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have a contraindication to start on standard 4-drug TB
therapy, have been treated for TB in the last two years,
have unknown HIV status and are unwilling to be tested,
or if they are pregnant at study enrollment (Table 1). In
addition, participants who are HIV positive are excluded
from the pharmacokinetic cohort (Aim 2 only).
Recruitment and assessment of primary objectives
Study fieldworkers will approach all patients initiating
TB treatment who meet the study’s eligibility criteria for
screening and potential enrollment. If the patient is eli-
gible and willing to participate, then written informed
consent is obtained on the same day as TB treatment
initiation. Immediately following study enrollment, a
study nurse collects socio-demographic information and
conducts behavioral assessments of the participant in-
cluding participant questionnaires on lifetime and recent
alcohol use, which is confirmed through biomarker ana-
lysis, further described below. Participants identified as
having problem alcohol use are offered a referral to local
substance abuse treatment services. If not completed by
the clinic as part of the work-up for the current episode
of TB disease, all participants receive chest radiographs.
A baseline sputum specimen is collected for acid fast
bacilli (AFB) smear and mycobacterial culture along with
minimal inhibitory concentrations (MICs) for isoniazid,
rifampin, ethambutol, and pyrazinamide, and blood
samples are drawn to assess complete blood count (CBC),
alanine transaminase (ALT), aspartate transaminase
(AST), creatinine (Cr), prothrombin time (PT)/inter-
national normalized ratio (INR), albumin, and hemoglobin
A1C (HbA1c) (Table 2). From treatment records of study
participants, clinical data on previous TB disease, Xpert
MTB/RIF result, AFB smear results, mycobacterial culture
result, HIV status, and medical history is extracted. For the
primary outcomes for Aim 1 and 2, participants provide
weekly first morning sputum samples during the first 12
treatment weeks to assess rate of sterilization/culture
conversion. Follow up interviews are performed monthly
for the 6 treatment months during which a brief
interviewer-administered questionnaire on alcohol use and
TB medication side effects evaluation is performed by the
study nurse. If there is a positive side effect screen at any
appointment, blood is drawn to test for CBC, Cr, ALT and
AST. A final sputum specimen is collected after completion
of five months of treatment to assess treatment outcome,
as defined by the WHO. After treatment completion (as de-
fined by the clinic), participants are interviewed at 3, 6, 9,
and 12 months post-treatment regarding alcohol use (Table
2) and screened for any re-occurrence of TB symptoms.
Those with a positive TB symptom screen are referred to
the clinic for microbiologic assessment.
For Aim 2, 200 HIV-negative participants from the
original cohort are co-enrolled in a single 8-h session
with intensive PK/PD studies of isoniazid, rifampin, eth-
ambutol, and pyrazinamide during treatment weeks 4–8,
that is after the patient has completed one month of
treatment and before they transition to the continuation
phase of treatment. During this session, the antitubercu-
losis drugs are administered by the study nurse under
fasting conditions and blood samples are obtained im-
mediately before the dose, then again at 1.5, 3, 5, and
8 h after the dose is ingested. Plasma samples are stored
frozen at − 80 °C freezer until analysis.
Evaluation of alcohol and other substance use
TRUST uses detailed, repeated measure documentation
of participant medication adherence and alcohol con-
sumption during TB treatment to identify alcohol-re-
lated biologic causal mechanisms that interfere with TB
treatment response. Drinking behavior of participants is
assessed in the form of frequency, quantity, volume, pat-
terns and types of alcohol consumption using the Alco-
hol Timeline Follow Back (TLFB) technique [27].
Additionally, the 10-item Alcohol Use Disorders Identifi-
cation Test (AUDIT) is used to assess lifetime hazardous
and harmful patterns of alcohol use [28]. The Fager-
ström Test for Nicotine Dependence (FTND) is
administered to assess current tobacco use and depend-
ence [29], and in addition to dedicated illicit drug history
Table 1 TRUST Participant Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
● At least 15 years old ● Treated for TB in the last
2 years (defined as at least
1 month of TB treatment)
● Initiating TB treatment ● Have RIF-resistant TB (RIF
resistance will be known at
screening from Xpert MTB/RIF)
● Expect to remain in the
local area for the next
2 years
● Extrapulmonary TB
● Agree to comply with all
study requirements, including
provision of contact information
and attendance at all study
appointments
● Contraindication to start on
standard 4-drug therapy
● Provide written, informed
consent to participate in the
study if ≥18 years of age or
written individual consent
and separate parental
consent if < 18 years
● No documented HIV status
from the previous 6 months
and refuse HIV testing
● Pregnant at study enrollment
● History of epilepsy
● Do not speak English or
Afrikaans
● HIV seropositive (for Aim
2 only)
Abbreviations: TB, tuberculosis, RIF, rifampin
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taking, the 11-item Drug Use Disorders Identification
Test (DUDIT) is administered to assess for harmful pat-
terns of illicit drug use and dependence [30]. Depression
is assessed with the Center for Epidemiologic Studies
Depression Scale (CES-D) [31] and the Household Hun-
ger Scale (HHS) is used to assess food security [32]. The
innovative repeated measures design (Table 2) enables
us to capture alcohol use changes over the course of
treatment, as for example, we hypothesize that patients
may report less alcohol use around the time of treatment
initiation when they are feeling ill and then return to
drinking heavier amounts as their health improves. Add-
itionally, self-report, on the various baseline alcohol
measures described above, is validated using phosphati-
dylethanol (PeTH) measurement at the baseline assess-
ment. PeTH is a biomarker of alcohol consumption in
the preceding 30 days and will be measured from dried
blood spots sent to United States Drug Testing
Laboratories in Des Plaines, IL [33]. By validating stan-
dardized, repeated alcohol measures with a baseline
blood based biomarker, we aim to substantially reduce
misclassification of alcohol use compared with studies
which to date have largely relied solely on chart biopsy.
Evaluation of adherence
In order to capture comprehensive data on adherence in
those with problem alcohol use, TRUST has developed a
system for patient engagement including active tracking of
participants with daily documentation of their pill-taking
by a team of study-employed DOT workers, coupled with
frequent reminders and graded subject reimbursements
based on adherence. During the 6-month treatment
period, pill-taking is documented by these DOTs workers
using smartphones on weekdays and self-report is
collected on Mondays to document the preceding week-
end compliance. DOT workers submit adherence data to
a central server on a daily basis for regular review of cu-
mulative indicators by the TRUST team, allowing for
real-time identification of participants needing increased
outreach to remain engaged in care. DOT workers also
collect the weekly sputum specimens during the first
12 weeks of treatment so that the onus is not on the par-
ticipant to deliver the specimens. In addition to reim-
bursement for regular study visits, TRUST employs
graded reimbursement in the form of grocery vouchers
based on percent of DOT visits and weekly sputa captured
successfully during the first three months of treatment.
Table 2 SPIRIT Figure
STUDY PERIOD
Enrolment Allocation During Treatment Months Post Treatment Months
TIMEPOINT − 1 0 1 2 3 4 5 6 3 6 9 12
ENROLMENT:
Eligibility screen X
Informed consent X
Chest X-Ray X
HIV Testing X
Urine pregnancy test X
Allocation X
INTERVENTIONS:
Weekday DOT & weekend self-report X X X X X X X
PK/PD evaluationa X
Sputum specimensb X X X X X
Blood specimensc X
ASSESSMENTS:
Side effects screen X X X X X X
TLFB X X X X X X X X X X X
Behavioral Assessmentd X X X X
TB Symptom Screen X X X X
aThe PK/PD visit is completed between weeks 4 and 8 of treatment for the Aim 2 cohort only
bCollected during screening, then weekly for weeks 1–12 of treatment, with a final specimen at month 5
cBlood is drawn at the initial visit for complete blood count (CBC), alanine transaminase (ALT) and aspartate transaminase (AST), albumin, creatinine (Cr),
international normalized ratio (INR), and partial thromboplastin time (PTT), hemoglobin A1c (HbA1c) and Phosphatidylethanol (PEth). In the event of a positive
side effect screen, the following levels will be reassessed: assessed in the event of a positive side effect screen: Complete blood count (CBC), alanine transaminase
(ALT) and aspartate transaminase (AST), and creatinine (Cr)
dThe behavioral assessment includes Fagerstrom, AUDIT, DUDIT, CES-D and Household Hunger Screening
Myers et al. BMC Infectious Diseases  (2018) 18:488 Page 5 of 9
Analysis
Sample size assumptions
In recent studies in Western Cape Province, 20–30% of
patients on standard therapy had mycobacterial growth
in MGIT sputum cultures after 8 weeks of therapy (per-
sonal communication, Mark Hatherill, MD) with roughly
50–60% of TB patients in the region reporting recent al-
cohol use [34, 35]. Our goal enrollment of 438 patients
is based on a logrank test to estimate the power to de-
tect the difference in time to positive sputum culture
with and without problem alcohol consumption.
More specifically, with 291 participants (87 partici-
pants being problem alcohol drinkers), assuming a 5%
drop-out rate at 12 weeks, and varying levels of survival
among those without problematic alcohol consumption
and 80% power, if 15% of those without problematic al-
cohol have a positive culture at 12 weeks, then we will
be able to detect a HR of 0.63. In order to be able to
stratify participants based on treatment adherence (those
taking < 80% of medication doses), we inflated the 291
by 5% and then inflated by an additional 30% for HIV
positive participants. This would mean recruiting 438
participants for Aim 1 (307 HIV negative). For Aim 2,
we used the same model and aim to recruit 200 partici-
pants from the 307 HIV negative, omitting any individ-
uals who do not want the full day of phlebotomy or not
able to participate due to their schedule. This will allow
us to detect a HR of 0.57, indicating 0.34 in the alcohol
group having positive cultures at 12 weeks.
Assessment of the study endpoints/primary objectives
For the primary analysis, problem alcohol use will be
assessed using both continuous and categorical measures
to determine the frequency of acute exposure and the
regularity of alcohol ingestion. We will use basic bivari-
ate tests to assess the association between alcohol use
and the primary TB outcomes (time to positivity at
12 weeks), as well as the association between potential
confounders and problem alcohol use. We will investi-
gate the role of mediating factors by estimating the dir-
ect, indirect, and total effects of alcohol use with
nonlinear models on our outcomes of time to positivity
(TTP) and poor TB outcomes, including death, treat-
ment failure, and relapse. We will control for HIV as a
potential confounder and, if necessary, stratify our re-
sults by HIV status. Using poisson, negative binomial, or
Cox proportional hazards models as appropriate, we will
model TTP and poor TB outcomes. Additionally, we will
investigate potential threshold effects of alcohol by using
a penalized spline for alcohol in the model and assessing
nonlinear patterns graphically and with statistical tests.
We will further investigate the distinction between acute
versus chronic effects of alcohol on TTP by fitting three
different models: acute consumption patterns, chronic
measures of alcohol, or both acute and chronic alcohol
exposures, and use fit statistics to assess the best fitting
model. We will also model the use of alcohol during the
course of the study as a function of TB disease severity
using a repeated measures model based on self-reported
alcohol usage at each time point. All models will assess
goodness-of-fit. Analyses will be performed in R
(r-project.org) and SAS (SAS Institute, Cary, NC).
For the second objective, we will investigate the effect
of problem alcohol use on the PK measures peak serum
concentration (Cmax) and area under the curve (AUC)
and the effect on sterilizing activity, with adjustment for
drug concentrations and mycobacterial drug minimal
inhibitory concentration (MIC). We will identify other
potential modifiers of the alcohol-drug concentration-
sterilization relationship, including BMI, gender, and
age, and use these findings to build a prediction model
of who is at highest risk of low PK with delayed PD. We
will also assess how these other modifiers explain
variability in PK/PD seen in the control, non-problem al-
cohol population.
Innovative modeling techniques
In order to incorporate the variability of Mycobacterium
tuberculosis drug susceptibility and the complexity of
the multidrug pharmacokinetic relationship, we will
model the nonlinear effects of TB drug exposure to-
gether with MIC and the interaction between drug expo-
sures, on sterilizing activity [36] in participants exposed
to alcohol compared to those without alcohol exposure.
This nonlinear semi-mechanistic model uses TTP data
in sputum liquid cultures at 12 weeks as a surrogate of
bacillary burden to describe the biexponential decline in
bacillary load using the α- and β-slopes.
The slowly declining M. tuberculosis subpopulation is
thought to represent ‘persister’ bacilli and their rate of
kill is thought to correspond to sterilizing activity of the
regimen, defined as β-slope. Using a multivariate adap-
tive regression splines (MARS) analysis, individual esti-
mates of β-slope will be generated by the model for
evaluation of the effects of drug exposure on sterilizing
activity. As drug interactions can be additive, synergistic
or antagonistic, by using this non-parametric regression
data analysis technique, we will be able to combine re-
cursive partitioning into sub regions of interest with fit-
ting of splines to variables to determine relationships
within the sub-regions in the dataset. Potential predic-
tors of the primary outcome (i.e. the β- slope) included
in the MARS analysis will be problem alcohol use (ver-
sus non), PK measurements, individual drug MICs, the
percentage of the 24-h dosing interval that concentra-
tion exceeded MIC and any other variables found to sig-
nificantly predict final outcomes in the initial analysis.
By confirming preliminary findings of variability of
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specific drug PK among participants and the association
with 12-week culture conversion and rate of decline in
slowly dividing M. tuberculosis subpopulations (β-slope
or sterilizing activity) in the PD model, we will be able
to evaluate if drug dosing in participants using alcohol
requires more intensive monitoring and if dose regimens
should specifically be adjusted for alcohol.
Finally, we will use mediation analysis methods to esti-
mate both the direct and indirect effects of alcohol on
TB treatment outcomes in the presence of potentially
mediating effects of adherence and medication PK [37].
Project status
Recruitment began in May 2017 and is expected to
complete by October 2020.
Discussion
TRUST will define the physiologic role of alcohol use on
TB treatment outcomes independent of its behavioral ef-
fects, thus introducing a new paradigm of how to craft
interventions to improve outcomes for this population.
The anticipated challenges inherent in studying this
at-risk population are high participant attrition and low
enrollment; however, we have built a system robust
against attrition through comprehensive collection of in-
formation on how to locate and contact participants, ac-
tive tracking and engagement of participants between
appointments using DOT workers and mobile technol-
ogy, and consistent provision of reminders and reim-
bursement to minimize loss to follow up.
Through TRUST’s novel approach of using repeated
validated alcohol measures along with collection of com-
prehensive treatment adherence information, we aim to
determine the contribution of acute versus chronic alco-
hol use on TB treatment response, leading to an im-
proved understanding of how long alcohol effects persist
and inform tailored treatment for patient populations
with this modifiable TB risk factor.
Furthermore, though modeling, TRUST aims to
change the approach to optimizing drug dosing for TB,
with the potential to improve therapeutics for patients
with co-morbid problem alcohol use. For instance,
higher doses of isoniazid and rifampin have been dem-
onstrated to be well-tolerated in clinical trials [38, 39],
so should we find either consistently low PK or delayed
effectiveness of these two drugs among alcohol users,
empiric increased dosing of either drug could be further
studied. Alternatively, if one of the first line drugs is
found to consistently underperform, consideration could
be given to substituting an alternative TB medication
such as a fluoroquinolone; this substitution has been
shown to be non-inferior to standard therapy [40]. The
findings from the TRUST study may inform blanket regi-
men modification for problem alcohol users, or tailored
modifications based on a risk profile of those at risk of
low PK or delayed PD based on our prediction model.
Our prospective investigation of the relation between
problem alcohol use and TB treatment will provide the
basis for identifying novel interventions to improve cure
rates in TB patients with co-morbid problem alcohol
use. TRUST will inform new strategies for addressing
the complex interactions between these diseases, which
could include risk profiling to identify patients with
problem alcohol use, innovative medication dosing,
medication substitutions, changes in adherence monitor-
ing, and extending length of treatment.
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